Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments ...

AbbVie (ABBV) has agreed to acquire clinical-stage biotechnology company Capstan Therapeutics for up to $2.1 billion in cash.

AbbVie will pay up to $2.1 billion in cash at closing to acquire Capstan, subject to certain customary adjustments.

The drugs are projected to bring in more than $31 billion in combined sales by 2027. For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments.

AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.

AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today ...

AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

(Reuters) -U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion, expanding its pipeline with experimental treatments ...

AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B The acquisition will expand AbbVie’s exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the ...

Shares of AbbVie Inc. ABBV slipped 2.40% to $182.31 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) announced Wednesday positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating ...